Caprihans India manufactures and sells specialized PVC and PVDC films used primarily for pharmaceutical blister packaging and other industrial applications. The company generates revenue by supplying these barrier films to domestic and global drug manufacturers to ensure product safety and shelf-life.
While the company operates in a regulated niche (pharma packaging), the financial results show no evidence of a moat, with net margins near zero and negative ROCE in recent years. The lack of pricing power is evident as raw material inflation and USD appreciation have historically eroded margins to the point of net losses.
Capital allocation has been poor, characterized by a massive slump sale acquisition from its parent (Bilcare) that brought significant debt and legacy liabilities. Recent actions include selling real estate to pay down debt and issuing warrants to the promoter to address working capital shortages.
The company collapsed under the weight of its parent's legacy sins. The massive assumption of matured public deposits and the unrecoverable inter-corporate deposits with Anax Industries proved to be a terminal drain on liquidity. As working capital dried up, the business could no longer fund operations, and the promoter's warrant infusions were merely throwing good money after bad. The supposed margin of safety was an illusion; the book value evaporated through continuous provisioning for bad debts and the eventual forced liquidation of remaining assets to satisfy angry creditors and depositors.
RichFakir rates Caprihans India Ltd's business quality as poor — 17/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
RichFakir's educational verdict on Caprihans India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
View the full live analysis →